arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nurix Therapeutics, Inc.

NRIX
$25.53 ▲ +0.31 (+1.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nurix Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.8B
Dividend Yield
Revenue Growth -79.5%
Op. Margin None
ROIC -23.3%
FCF / Share $-0.89
Trailing P/E
Price / Book 6.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.04M
↓ -79.5%
Net Income Profit after all expenses
$-87.17M
↓ -54.7%
Operating Margin Operating profit as % of sales
-109.7%
↑ +67.8% 0th
FCF / Share Free cash flow per share
$-0.89
↓ -33.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
17
Cash Quality
65

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 31 quarters